ALL HYPOTHESES
Repurposing candidates for ocrelizumab
Rheumatoid arthritis 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| CD20 | CDAI | 0.333 | High | novel signal | none | |
| cytokines | rheumatoid arthritis | 0.220 | Mid | reproduces known | completed |
ALL HYPOTHESES
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| CD20 | CDAI | 0.333 | High | novel signal | none | |
| cytokines | rheumatoid arthritis | 0.220 | Mid | reproduces known | completed |